Literature DB >> 14720132

Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?

Tammy O Tengs1.   

Abstract

OBJECTIVE: The US Public Health Service Panel on Cost-Effectiveness has recommended the use of quality-adjusted life-years (QALYs) as the best way to estimate outcomes in a cost-effectiveness analysis. We evaluate the importance of this recommendation by assessing whether adjusting for health-related quality of life affects the ultimate resource allocation decision implied by the cost-effectiveness ratio for interventions aimed at cancer prevention and control.
METHODS: We identified 110 interventions in 39 articles for which both cost/life-year and cost/QALY were reported. Interventions were forms of prevention, early detection, or treatment of cancer. We calculated a Spearman correlation to assess the ordinal relationship between cost/life-year and cost/QALY. In addition, we employed various decision thresholds to assess whether the use of cost/life-year would yield different resource allocation decisions than the use of cost/QALY.
RESULTS: The correlation between cost/life-year and cost/QALY is 0.96 (P <.0001). Assuming a US dollars 50000 decision threshold, adjustment for quality of life would affect the implied choice in 5% of cases. With a US dollars 400000 threshold, adjustment for quality of life would affect choice for 2% of interventions.
CONCLUSIONS: For interventions aimed at cancer, the outcome measures of cost/life-year and cost/QALY are highly correlated with one another. Although adjusting for quality of life can make an important difference in the evaluation of alternative approaches to cancer prevention and control, it often does not.

Entities:  

Mesh:

Year:  2004        PMID: 14720132     DOI: 10.1111/j.1524-4733.2004.71246.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  14 in total

Review 1.  A systematic review of the key indicators for assessing telehomecare cost-effectiveness.

Authors:  Stephanie Vergara Rojas; Marie-Pierre Gagnon
Journal:  Telemed J E Health       Date:  2008-11       Impact factor: 3.536

Review 2.  Using QALYs in cancer: a review of the methodological limitations.

Authors:  Martina Garau; Koonal K Shah; Anne R Mason; Qing Wang; Adrian Towse; Michael F Drummond
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

3.  Estimated effects of the National Breast and Cervical Cancer Early Detection Program on breast cancer mortality.

Authors:  Thomas J Hoerger; Donatus U Ekwueme; Jacqueline W Miller; Vladislav Uzunangelov; Ingrid J Hall; Joel Segel; Janet Royalty; James G Gardner; Judith Lee Smith; Chunyu Li
Journal:  Am J Prev Med       Date:  2011-04       Impact factor: 5.043

4.  Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.

Authors:  Christian Ewelt; Mathias Goeppert; Marion Rapp; Hans-Jakob Steiger; Walter Stummer; Michael Sabel
Journal:  J Neurooncol       Date:  2010-10-16       Impact factor: 4.130

5.  The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection.

Authors:  Harrell W Chesson; Kyle T Bernstein; Thomas L Gift; Julia L Marcus; Sharon Pipkin; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-05       Impact factor: 2.830

Review 6.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

7.  Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy.

Authors:  Michael K Wong; Xufang Wang; Maruit J Chulikavit; Zhimei Liu
Journal:  Am Health Drug Benefits       Date:  2013-07

Review 8.  Willingness to pay for cancer prevention.

Authors:  Timothy L Hunt; Bryan R Luce; Matthew J Page; Robin Pokrzywinski
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Psychometric evaluation of the WHOQOL-BREF in community-dwelling older people in Taiwan using Rasch analysis.

Authors:  Wen-Miin Liang; Chih-Hung Chang; Yi-Chun Yeh; Haw-Yaw Shy; Hung-Wei Chen; Mau-Roung Lin
Journal:  Qual Life Res       Date:  2009-04-02       Impact factor: 4.147

10.  Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer.

Authors:  M Martín-Jiménez; A Rodríguez-Lescure; M Ruiz-Borrego; M-A Seguí-Palmer; M Brosa-Riestra
Journal:  Clin Transl Oncol       Date:  2009-01       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.